RegMed sector, remember the children in Sandy Hook; our eyes tear with you

Wednesday, 19 December 2012

*The 6 W’s: Who, what, where, when, why and what of it …*

* *

*Words to remember … “We bear a responsibility for every child … This is our first task, caring for our children. It’s our first job. If we don’t get that right, we don’t get anything right,” Obama told a packed auditorium at Newtown High School at the end of a somber multi-faith service. “Surely we can do better than this.”*

*RegMed stocks added to gains for … just 8 up equities including ASTM, BMTI, DNDN, IMUC, KOOL, NBS, PROT and RENE.L and pain Monday … while 12 headed downward … at the open! As we progressed through the day … the dominance factor is sellers versus buyers as the mantra is … sell the strength and news – if any.*

*What is happening with Cytori (CYTX) after Friday’s overnight offering – it was down at the close and opened lower and is trading at -$0.01 to $2.83 as investors pick at the “trailing” pricing of the after-market. One of the many comments … **“Didn’t see that coming!! For all their hype, really don’t have a lot of revenue. Now that they are doing trials, big burn”!*

*Ongoing “fiscal cliff” discussions have kept investors cautious over the last few weeks, as Democrats and Republicans attempt to thrash out a deal to resolve the looming economic difficulties.*

*Who is up – Advanced Cell Technology (OTC: ACTC +$0.001), Athersys (ATHX +$0.01), BioMimetic (BMTI +$0.02), BioTime (NYSE MKT: BTX +$0.04), Dendreon (DNDN +$0.11), ImmunoCellular (NYSE MKT: IMUC +$0.08), NeoStem (NYSE MKT: NBS +$0.01), ThermoGenesis (KOOL+$0.026) and Verastem (VSTM +$0.17).*

*Mid-Day: The NASDAQ is UP + 30.36 (+1.02%) to 3,001.70 while the Dow is also UP +83.32 (+0.63%) to 13,218.33.** *

*Measuring the day – NEGATIVE – 11 green (ups) following 15 red (downs) and 5-6 fluctuating black (flats) … The CBOE Volatility Index traded below 17.*

* *

*My Model Portfolio and Indicators:*

Â· *Aastrom (ASTM) is FLAT … at $1.38 after a few good days of positive trading and volume growth with a tighter mid-day range of $1.35 – $1.40 with small 62 K volume … compared to Friday’s closing range of $1.35 – $1.48 with much larger volume of 489.6 K. From a number of calls – Dan Orlando, the interim CEO did a great job of presenting the company at the Oppenheimer conference. I have maintained a “BUY” in this market and at this pricing because of the late stage trial status.***

Â· *BioLife Solutions (OTC: BLFS) is FLAT … at $0.26 … As, I continue to state … the joys of a rising stock price and the sorrow in profit taking by day trader and investors with a flat trading range of $0.26 – $0.26 … with only thin 7 K share volume compared to Friday’s closing range of $0.26 to $0.26 and larger 4.8 share volume. I continue to reiterate this as a “BUY” on downdraft … still sticking to BLFS being under-valued –with a $0.50 target! Yet again … don’t worry those same traders will be back as they can NOT keep this equity down!!*

Â· *Cytori (CYTX) is DOWN … -$0.01 or -0.35% to $2.83 … after an offering at $2.85 for $18.5 M with a trading range of $2.80 – $2.88 and large post offering volume of 215 K shares from Friday’s closing wide range of $2.74 – $2.88 with 3.713 M volume … I project… a “HOLD” for … until the offering settles out …as I am NOT sure how CYTX will “trade” during this after-market period;** *

Â· *Cytomedix (OTC: CMXI) is DOWN … -$0.037 or -5% to $0.703 with a tighter trading range of $0.69 to $0.71 with very low volume of 8.5 K shares from Friday’s closing range of $0.68 to $0.74 and larger 61.8 K share volume. CMXI is undervalued and ranked a “BUY” as most recently stated it was worth $1.25 … at a minimum.*

Â· *NeoStem (NYSE MKT: NBS) is UP… +$0.01 or +1.54% at $0.64 … with a “hair” tighter but, moving up day’s range of $0.63 -$0.65 … with low 183 K volume so far from Friday’s closing range of $0.62 – $0.65 with moderate 414.3 K share volume. I believe NBS continue a “BUY” as I have been iterating for a while! But, day traders, retail and individual investors are slowing the year down!*

* *

*Worth mentioning:*

Â· *France’s Vivalis is set to buy Intercell in a deal valuing the Austrian vaccine maker at around 133 M euros ($174 M), and creating an enlarged player in the European biotech industry. Both companies are loss-making and the tie-up, billed as a merger of equals, will allow for cost savings of 5 million to 6 M euros a year, the companies said on Sunday. The combined group – to be known as Valneva, with listings in Paris and Vienna – also plans to raise 40 M euros via a rights issue to strengthen its balance sheet. Former Vivalis shareholders will hold approximately 55% of the combined entity and Intercell investors 45%, immediately after the deal completes. The decision to merge with Vivalis follows a difficult period for Intercell, which has a vaccine for Japanese encephalitis on the market, but has been struggling to get back on track after a string of product setbacks. For Vivalis, the acquisition offers an opportunity to accelerate its drive to establish a profitable business based on finished products.*

Â· *Fibrocell Science (OTC: FCSC)plans to initiate a P2 clinical trial to assess the potential of azficel-T for treating restrictive burn scars in !Q1/13. Fibroblasts are skin cells responsible for the production of collagen that contribute to the formation of connective tissue fibers. The company recently launched LAVIV^® (azficel-T), the first and only personalized cell treatment approved by the FDA to improve the appearance of moderate to severe nasolabial folds or “smile line” wrinkles in adults. Azficel-T has been evaluated in over 1,000 patients in well controlled clinical studies, including two pivotal Phase III trials for licensed application. The restrictive burn scar trial will enroll 20 subjects who have unilateral restrictive burn scars of a jointed area, such as elbows, shoulders and fingers. Measurement scales will assess Range of Motion (ROM), Brief Pain Index and Scar Appearance. Approximately 45,000 people in the U.S. are hospitalized each year with severe burns. These patients are often left with restrictive burn scars that decrease mobility and cause continuous pain. “Indications are that fibroblasts, due to their inherent role in wound healing, have the potential to bring an increased quality of life to those patients who have long suffered from restrictive burn scars. This clinical trial has the potential to help validate this concept and bring physicians an effective treatment option for their patients.”*

» Full news story